More on TYRA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $22.01 |
|
|||
| Open | $21.41 | ||||
| 52 Wk High | $0.22 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $23.43 | ||||
| Day Low | $21.27 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,430,752 | ||||
- Cantor Fitzgerald Reiterates Overweight Rating on Tyra Biosciences (TYRA)
- Tyra Biosciences reports Phase 2 data for oral bladder cancer drug
- Piper Sandler Reiterates Overweight Rating on Tyra Biosciences (TYRA) Ahead of Dabo IR NMIBC Readout
- H.C. Wainwright Reiterates Buy Rating on Tyra Biosciences (TYRA)
- Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP
- Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
- Tyra Biosciences (TYRA) PT Lowered to $42 at Jefferies
- Tyra Biosciences, Inc. (TYRA) Misses Q2 EPS by 4c
- Form 424B5 Tyra Biosciences, Inc.
- Form 10-Q Tyra Biosciences, Inc. For: Jun 30
Entities mentioned with TYRA
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Jefferies & Co | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
